“Progress continues across our TARA-002 clinical development programs, with patient dosing now underway in the ADVANCED-2 trial in patients with non-muscle invasive bladder cancer (NMIBC) and the STARBORN-1 trial in pediatric patients with lymphatic malformations (LMs),” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We remain keenly focused on execution across all our ongoing clinical studies and remain on track to report preliminary results from the expansion portion of the ADVANCED-1 trial of TARA-002 in patients with NMIBC in the first half of 2024. With a cash runway into the second quarter of 2025, we believe we are well positioned to achieve key milestones in our TARA-002 development programs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TARA:
- Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
- Protara Therapeutics doses first patient in Phase 2 STARBORN-1 trial of TARA-002
- Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
- Guggenheim bullish on Protara after dosing of first patient in ADVANCED 2 trial
- Protara announces dosing of first patients in Phase 1b/2 ADVANCED-2 trial
